who should receive early anti-tnf therapy: with what benefits and risks?
Published 10 years ago • 1.4K plays • Length 18:23Download video MP4
Download video MP3
Similar videos
-
16:10
when should we stop anti-tnf therapy and how do we then treat the patient?
-
11:37
debate: is combination therapy necessary if you use anti-tnf? - yes
-
14:56
debate: is therapeutic drug monitoring necessary with anti-tnf therapy? - yes
-
20:54
selection and use of the non-anti-tnf biological therapies? who? when? how?
-
7:36
debate: is combination therapy necessary if you use anti-tnf? - no, monotherapy will suffice
-
12:35
best of the day: acg2016 - anti-tnf therapy
-
12:32
use of anti-tnf therapies for crohn's disease
-
14:13
what do we do when the patient loses their response to an anti-tnf?
-
20:00
what factors influence choice of first therapy in ibd: how can we predict response and be smarter?
-
3:35
tnf inhibitors: an overview
-
20:04
is there an optimal approach to prevent recurrence in post-operative crohn's disease
-
21:18
how can we prevent and manage the common side effects of immunomodulators and biologics?
-
18:38
positioning anti-il-12 and anti-il-23 inhibitors
-
21:59
the treatment of moderate to severe ibd with anti-tnf biologics and immunomodulators
-
26:25
understanding non-response and loss of response in ibd: which is it and when do we change classes?
-
21:25
first-line therapy options in ibd: understanding longitudinal severity
-
18:01
debate: combination or monotherapy with anti-tnf? - combination
-
21:53
right drug for the right patient
-
23:55
new biologic therapies that target the il-12/23 pathway